SCHEMBL10062707

SCHEMBL10062707

CC(=O)[C@H](C)NP1(=O)OC[C@H]2O[C@@H](n3ccc(N)nc3=O)[C@](C)(O)[C@@H]2O1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE3A Q14432 3/20 0.38
▸ PDE4D Q08499 1/20 0.38
▸ SLC29A1 Q99808 1/20 0.38
▸ POLA1 P09884 2/20 0.37
▸ LMNA P02545 3/20 0.34
▸ CACNA1F O60840 2/20 0.34
▸ ALB P02768 2/20 0.34
▸ MAPT P10636 2/20 0.34
▸ CACNA1D Q01668 2/20 0.34
▸ CACNA1S Q13698 2/20 0.34
▸ CACNA1C Q13936 2/20 0.34
▸ STING1 Q86WV6 1/20 0.34
▸ THRB P10828 1/20 0.33
▸ MTOR P42345 1/20 0.33
▸ MDM2 Q00987 1/20 0.33
▸ NCOA1 Q15788 1/20 0.33
▸ NCOA3 Q9Y6Q9 1/20 0.33
▸ POLG P54098 2/20 0.32
▸ FGFR1 P11362 1/20 0.32
▸ POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14147838 0.90 PDE3A (0.37) PDE3APDE4DSLC29A1POLA1LMNA
SCHEMBL2064784 0.90 PDE3A (0.37) PDE3APDE4DSLC29A1POLA1LMNA
SCHEMBL16502047 0.88 POLA1 (0.36) PDE3APDE4DSLC29A1POLA1LMNA
SCHEMBL16493905 0.88 POLA1 (0.34) PDE3APDE4DSLC29A1POLA1LMNA
SCHEMBL10062708 0.88 POLA1 (0.36) PDE3APDE4DSLC29A1POLA1LMNA
SCHEMBL2065937 0.87 POLA1 (0.34) PDE3APDE4DSLC29A1POLA1LMNA
SCHEMBL2065520 0.87 POLA1 (0.37) PDE3APDE4DSLC29A1POLA1LMNA
SCHEMBL2065433 0.87 POLA1 (0.35) PDE3APDE4DSLC29A1POLA1LMNA
SCHEMBL10062712 0.86 FGFR1 (0.39) PDE3APDE4DSLC29A1POLA1LMNA
SCHEMBL2889203 0.86 PDE3A (0.38) PDE3APDE4DSLC29A1POLA1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148349-B2 Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2012-04-03 — — US disclosed
US-20100022468-A1 NUCLEOSIDE CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION MERCK SHARP & DOHME LLC 2010-01-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022468-A1 NUCLEOSIDE CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION RNGTT, NSUN2, RNASE1 PDE3A 484/4885PDE4D 368/4885SLC29A1 66/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback